Results 51 to 60 of about 37,133 (255)

Bendamustine plus rituximab is an effective first-line treatment in hairy cell leukemia variant: A report of three cases [PDF]

, 2017
Hairy cell leukemia variant (HCLv) is a chronic lymphoproliferative disorder classified as a provisional entity in the 2016 WHO Classification of Lymphoid Tumors.
Berno, Tamara, Bertorelle, Roberta, Facco, Monica, Frezzato, Federica, Imbergamo, Silvia, Piazza, Francesco, Piva, Elisa, Pizzi, Marco, Riva, Marcello, Scomazzon, Edoardo, Semenzato, Gianpietro, Trentin, Livio, Visentin, Andrea   +12 more
core   +1 more source

Frequent oncogenic BRAF V600E mutation in odontogenic keratocyst

Oral Oncology, 2017
Odontogenic keratocyst (OKC), also known as keratocystic odontogenic tumor (KCOT), has clinical significance due to its high incidence as well as high recurrence rate after surgical enucleation. Current clinical management for OCK is entirely dependent on surgical approach.
Yong Hoon Cha, Eunae Sandra Cho, Hee Eun Kang, Jaemin Ko, Woong Nam, Hyung Jun Kim, Nam Hee Kim, Hyun Sil Kim, In-Ho Cha, Jong In Yook   +9 more
openaire   +3 more sources

Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations [PDF]

Cancer, 2019
Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen‐activated protein kinase kinase (MEK) inhibitors for patients with PCPs ...
Tareq A. Juratli, Pamela S. Jones, Nancy Wang, Megha Subramanian, Simon J. B. Aylwin, Yazmin Odia, Elham Rostami, Olafur Gudjonsson, Brian L. Shaw, Daniel P. Cahill, Evanthia Galanis, Fred G. Barker, Sandro Santagata, Priscilla K. Brastianos   +13 more
openaire   +2 more sources

Relationship between BRAF V600E and clinical features in papillary thyroid carcinoma

Endocrine Connections, 2019
Objective: To investigate the mutant status of BRAF gene and analyze its relationship to epidemiological risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the largest, single-institution Chinese cohort to date ...
Changjiao Yan, Meiling Huang, Xin Li, Ting Wang, Rui Ling   +4 more
doaj   +1 more source

BRAF V600E Mutation of Non-Small Cell Lung Cancer in Korean Patients

Medicina, 2023
Background and Objectives: BRAF mutational status in resected non-small cell lung cancer (NSCLC) in the Korean population is poorly understood. We explored BRAF (particularly BRAF V600E) mutational status among Korean patients with NSCLC.
Hyo Yeong Ahn, Chang Hun Lee, Min Ki Lee, Jung Seop Eom, Yeon Joo Jeong, Yeong Dae Kim, Jeong Su Cho, Jonggeun Lee, So Jeong Lee, Dong Hoon Shin, Ahrong Kim   +10 more
doaj   +1 more source

Rapid BRAF mutation tests in patients with advanced melanoma:Comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform [PDF]

, 2018
BRAF mutational testing has become a common practice in the diagnostic process of patients with advanced melanoma. Although time-consuming, DNA sequencing techniques are the current gold standard for mutational testing.
Ascierto, Bowyer, Capper, Chapman, Coit, Colling, Davies, Deans, Dummer, Dvorak, Feller, Gentilcore, Greaves, Halait, Harle, Hauschild, Hyman, Ihle, Janku, Kerner, Kopetz, Lamy, McArthur, Melchers, Melchior, Menzies, Miotke, Parakh, Pellegrini, Ravishankar, Routhier, Schiefer, Wan, Wellbrock, Wellbrock   +34 more
core   +2 more sources

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source

Association between BRAF (V600E) mutation and clinicopathological features of papillary thyroid carcinoma: a Brazilian single-centre case series

Archives of Endocrinology and Metabolism, 2019
Objectives: We aimed to investigate the prevalence of the BRAF (V600E) mutation in consecutive cases of papillary thyroid carcinoma (PTC) in patients diagnosed and treated at the Hospital Sao Rafael (Salvador, BA, Brazil) and evaluate its association ...
Danielle Pessôa-Pereira, Mateus Fernandes da Silva Medeiros, Virna Mendonça Sampaio Lima, Joaquim Custódio da Silva Jr., Taíse Lima de Oliveira Cerqueira, Igor Campos da Silva, Luciano Espinheira Fonseca Jr., Luiz José Lobão Sampaio, Cláudio Rogério Alves de Lima, Helton Estrela Ramos   +9 more
doaj   +1 more source

Sensitive detection of BRAF V600E mutation by Amplification Refractory Mutation System (ARMS)-PCR [PDF]

, 2013
BACKGROUND: BRAF mutations occur in approximately 8% of all human cancers and approach 50% in melanoma and papillary carcinoma of thyroid. These mutations provide potentially valuable diagnostic, prognostic and treatment response prediction markers.
Jian Zhuge, Tiangui Huang, Wenyong W Zhang   +2 more
core   +1 more source

The neural crest‐associated gene ERRFI1 is involved in melanoma progression and resistance toward targeted therapy

Molecular Oncology, EarlyView.
ERRFI1, a neural crest (NC)‐associated gene, was upregulated in melanoma and negatively correlated with the expression of melanocytic differentiation markers and the susceptibility of melanoma cells toward BRAF inhibitors (BRAFi). Knocking down ERRFI1 significantly increased the sensitivity of melanoma cells to BRAFi.
Nina Wang, Qian Sun, Daniel Novak, Lei Zhu, Juliane Poelchen, Tamara Steinfass, Yiman Wang, Viktor Umansky, Jochen Utikal   +8 more
wiley   +1 more source